Otherwise, serious adverse events were reported in ~6% of participants and were evenly distributed across tirzepatide and placebo groups
Vivani Medical and Okava Pharmaceuticals have expanded their long-running partnership to develop the OKV-119 implant for dogs
This creates an ideal environment for carb cycling strategies
Diabetes Obes Metab 18(2):178185 Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ et al (2016) Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
While not dangerous, it was unexpected and is something researchers will continue monitoring in ongoing trials
The Role of Policy in Telehealth and GLP-1 Accessibility Healthcare policy has a direct impact on how accessible and effective telehealth can be